Drug intelligence / Profile preview

fluticasone propionate + ketotifen

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Topical, Inhalation, Intranasal, Ophthalmic, Oral

Overview

A combination of fluticasone propionate, a glucocorticoid with anti-inflammatory properties, and ketotifen, an antihistamine and mast cell stabilizer. This combination leverages complementary mechanisms to treat respiratory and allergic conditions. Fluticasone propionate reduces inflammation by suppressing inflammatory mediators, while ketotifen blocks histamine receptors and prevents the release of chemicals that cause allergy symptoms. The combination has shown efficacy in treating cough variant asthma in children and is also available as a topical formulation for skin conditions.

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on fluticasone propionate + ketotifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluticasone propionate + ketotifen.

Explore the full profile